Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul;88(7):729-40.
doi: 10.1007/s00109-010-0619-0. Epub 2010 Mar 31.

TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5

Johannes Lemke  1 , Andreas Noack, Dieter Adam, Vladimir Tchikov, Uwe Bertsch, Christian Röder, Stefan Schütze, Harald Wajant, Holger Kalthoff, Anna Trauzold
Affiliations

TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5

Johannes Lemke et al. J Mol Med (Berl). 2010 Jul.

Erratum in

  • J Mol Med. 2011 Apr;89(4):423

Abstract

Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) and agonistic anti-DR4/TRAIL-R1 and anti-DR5/TRAIL-R2 antibodies are currently under clinical investigation for treatment of different malignancies. TRAIL activates DR4 and DR5 and thereby triggers apoptotic and non-apoptotic signaling pathways, but possible different roles of DR4 or DR5 in these responses has poorly been addressed so far. In the present work, we analyzed cell viability, DISC formation as well as IL-8 and NF-kappaB activation side by side in responses to TRAIL and agonistic antibodies against DR4 (mapatumumab) and against DR5 (lexatumumab) in pancreatic ductal adenocarcinoma cells. We found that all three reagents are able to activate cell death and pro-inflammatory signaling. Death-inducing signaling complex (DISC) analysis revealed that mapatumumab and lexatumumab induce formation of homocomplexes of either DR4 or DR5, whereas TRAIL additionally stimulated the formation of heterocomplexes of both receptors. Notably, blocking of receptors using DR4- and DR5-specific Fab fragments indicated that TRAIL exerted its function predominantly via DR4. Interestingly, inhibition of PKC by Goe6983 enabled DR5 to trigger apoptotic signaling in response to TRAIL and also strongly enhanced lexatumumab-mediated cell death. Our results suggest the existence of mechanisms that silence DR5 for TRAIL- but not for agonistic-antibody treatment.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. FEBS Lett. 1998 Oct 2;436(2):139-43 - PubMed
    1. Oncogene. 2001 Jul 12;20(31):4258-69 - PubMed
    1. Clin Cancer Res. 2007 Jun 1;13(11):3403-12 - PubMed
    1. Oncogene. 2001 Jul 5;20(30):4101-6 - PubMed
    1. J Biol Chem. 2003 Nov 7;278(45):44338-47 - PubMed

Publication types

MeSH terms

LinkOut - more resources